Mushroom Extract, Cancer
In this video, Sensuke Konno spends about 27 minutes speaking on "Mushroom Extract, Cancer" at the 36th Annual Cancer Convention held on Labor Day weekend by the Cancer Control Society.
About Sensuke Konno
SENSUKE KONNO, Ph.D. received his M.S. and Ph.D. in Biochemistry and Molecular Biology from New York Medical College, Valhalla, New York in 1991.
After Dr. Konno completed his postdoctoral fellowship at the Department of Medicine, he was appointed for an Assistant Professor of Urology at New York Medical College in 1994. His research focuses on 3 prevalent urological malignancies such as prostate, renal and bladder cancers, and renal disorders/diseases including renal injury, diabetic nephropathy and kidney stones. His work has been presented and well received at numerous domestic and international meetings and also published in a number of the major medical and scientific journals.
About 10 years ago, due to the fact that there were currently no effective therapeutic options for urological cancers available, Dr. Konno started exploring an alternative, non-conventional approach, primarily focusing on specific mushroom extracts with anticancer activity. This study has been collectively described in a book: Maitake Magic, co-authored by Dr. Harry Preuss (Georgetown University, Washington D.C.). His initial work with these mushroom extracts on urological cancers has been extended to other cancers such as breast, lung, brain, liver and stomach cancers, and even to non-human malignancies in dogs and cats. Many Veterinarians use mushroom extracts with their animal patients.
Dr. Konno is currently serving as an Associate Professor and Director of Urology Research at New York Medical College. He is a member of American Urological Association (AUA) and American Association for the Advancement of Science (AAAS) since 1997. He also serves regularly as a moderator for the basic science sessions at the annual AUA meetings.
Dr. Konno may be contacted at his office by phone 914-594-3745 and e-mail [email protected].
Transcription
Okay. Good evening. I think some. It's been a long day for some people, but I think we still got the three or four hours to go. So I tried to make my presentation interesting. So everybody stay awake. And, you know, this hopefully this is going to be educational. So you learn something. OK. So having said that, I'm not talk about effects. So my take a different show on prostate, bladder, kidney and breast cancers or terms of an adjuvant therapeutic approach. But what that means. That's what I'm going to explain to you today. OK. What is my turkey diffraction? OK. It's a bioactive extract from my Turkey Musu, which is a tasty edible mushroom. You can see the picture right here. And actually, defection is a pretty good scam, which is protein bound, beta glucan. There's some reason this PowerPoint didn't come out right. But anyway, he has one protein portion and attached to peer Kim. Okay. Then this is a what better glucan looks like. It's a highly branched compound with a. You had one million doubt, which is a huge molecule. But who cares? I don't think, uh, not that many people. Yes. So I think you might be more interested in the next slides. That is by activity of diffraction. What does it do? Okay. Diffraction has a potent immune stimulatory activity that it's to boost up your immune system and also have antiviral activity to fight against viruses. Today, I'm going to focus on antitumor activity associated with induction of APEP ptosis, chemos, sensitizing activities, anti metastatic activity up, stop spreading cancers and also UNTAET carcinogenic activity to prevent the cancer growth.
OK. For antitumor activity or destruction, I'll be talking on three. Come on, you're rajko cancers, prostate, bladder and kidney cancers. That's why I mostly do. And I also spend little time more breast cancer. Okay. I try not to be too scientific or technical, but, you know, sometimes I had to do it. So try to make it easy for you anyway. This one shows the exam. I examine the effects of a defect show on prostate cancer cells. OK. And this one's called Dorsa depend on study to find out which concentration of the Deek fracture will be effective. So as you can see, about 240 microgram U.A.E 55 percent growth reduction. And go to 360. You get 75. And for 80 almost, you get complete growth inhibition. So diffraction is very effective in prostate cancer cells. And this is the same those who depend on study, but on bladder cancer cells. But same same trends, uh, diffraction can induce about 65 percent and 80 percent go through